ADAG
Adagene Inc.
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Neutral
-19/100
Last price
2.90
▼ 0.03 (1.02%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
2.90
Prev close
2.93
Day high
3.10
Day low
2.80
Volume
42.55K
Market cap
$194.72M
P/E (TTM)
—
52W range
1.30 – 4.85
Day trading desk
Gap from prior close
-1.02%
Prior close 2.93
VWAP
2.91
-0.22% from price
Relative volume
0.15×
Quiet session
Session range
5.00%
2.80 – 2.94
Position in range
71%
Near session high
ATR (14D)
0.27
9.47% of price
Prior day high
3.02
PDH
Prior day low
2.82
PDL
Bid / ask spread
—
Quote not published
Session volume
38.93K
Avg 252.44K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-9.37%
-10.9%
1M
-16.91%
-18.0%
3M
-24.68%
-27.7%
6M
-27.50%
-42.0%
YTD
+53.44%
+39.9%
1Y
+45.73%
+30.5%
3Y
+102.80%
+21.6%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on ADAG open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
7.65M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 14, 26 | DO CUONG VIET Director |
BUY | 2.00K | $7.50K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
DO CUONG VIET |
Director | 2.00K | Purchase |
Fundamentals
Market cap$194.72M
Enterprise value$91.46M
Revenue (TTM)$9.29M
Gross profit$9.29M
EBITDA$-21.95M
Net income$-20.51M
EPS (TTM)$-0.37
Free cash flow$-12.16M
Total cash$127.91M
Total debt$6.09M
Book value / share$1.33
Shares outstanding67.14M
Float42.09M
Short % of float3.68%
Dividend yield0.00%
Beta (5Y)0.54
Valuation & profitability ratios
Trailing P/E—
Forward P/E-5.18
PEG ratio—
Price / sales—
Price / book2.18
EV / revenue9.84
EV / EBITDA-4.17
Gross margin100.00%
Operating margin-1023.92%
Profit margin-220.77%
Return on equity-28.50%
Return on assets-13.95%
Debt / equity5.75
Current ratio5.02
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $7.67M | $103.20K | $18.11M | $9.29M | +7,332.8% |
| Operating revenue | $7.67M | $103.20K | $18.11M | $9.29M | +7,332.8% |
| Research & development | $22.03M | $28.78M | $36.64M | $81.34M | -23.4% |
| Selling, general & admin | $7.08M | $7.27M | $8.67M | $11.87M | -2.7% |
| Total operating expense | $29.11M | $36.05M | $41.83M | $93.21M | -19.3% |
| Operating income | -$21.44M | -$35.95M | -$23.72M | -$83.92M | +40.4% |
| Net interest income | $1.84M | $2.95M | $3.18M | -$315.82K | -37.6% |
| Pre-tax income | -$17.91M | -$33.44M | -$17.25M | -$79.51M | +46.5% |
| Tax provision | -$297.86K | -$17.55K | $1.69M | $459.06K | -1,596.9% |
| Net income | -$17.61M | -$33.42M | -$18.95M | -$79.97M | +47.3% |
| Net income to common | -$17.61M | -$33.42M | -$18.95M | -$79.97M | +47.3% |
| Basic EPS | -0.38 | -0.74 | -0.44 | -1.85 | +49.2% |
| Diluted EPS | -0.38 | -0.74 | -0.44 | -1.85 | +49.2% |
| EBIT | -$17.44M | -$32.59M | -$16.15M | -$78.82M | +46.5% |
| EBITDA | -$16.85M | -$31.65M | -$14.94M | -$77.37M | +46.7% |
| Basic shares | 47.20M | 45.03M | 43.79M | 43.31M | +4.8% |
| Diluted shares | 47.20M | 45.03M | 43.79M | 43.31M | +4.8% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $74.52M | $85.19M | $109.93M | $143.76M | — | -12.5% |
| Cash & short-term investments | $74.52M | $85.19M | $109.93M | $143.76M | — | -12.5% |
| Accounts receivable | — | — | — | $0 | $3.00M | — |
| Total current assets | $77.38M | $87.78M | $113.44M | $149.32M | — | -11.9% |
| Property, plant & equipment | $862.91K | $1.41M | $2.20M | $2.97M | — | -38.8% |
| Total assets | $78.26M | $89.27M | $115.73M | $152.40M | — | -12.3% |
| Total current liabilities | $25.17M | $38.18M | $31.46M | $55.08M | — | -34.1% |
| Current debt | $4.98M | $17.79M | $8.40M | $13.62M | — | -72.0% |
| Long-term debt | $1.14M | $417.34K | $13.54M | $14.15M | — | +172.7% |
| Total debt | $6.26M | $18.49M | $22.31M | $27.97M | — | -66.1% |
| Total liabilities | $42.91M | $38.74M | $45.17M | $69.31M | — | +10.8% |
| Retained earnings | -$328.79M | -$311.18M | -$277.75M | -$258.81M | — | -5.7% |
| Shareholder equity | $35.35M | $50.52M | $70.56M | $83.09M | — | -30.0% |
| Working capital | $52.20M | $49.59M | $81.99M | $94.24M | — | +5.3% |
| Net tangible assets | $35.35M | $50.52M | $70.56M | $83.09M | — | -30.0% |
| Shares issued | 59.23M | 58.89M | 55.15M | 54.07M | — | +0.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$17.61M | -$33.42M | -$18.95M | -$79.97M | — | +47.3% |
| Depreciation & amortisation | $589.79K | $938.86K | $1.21M | $1.45M | — | -37.2% |
| Stock-based compensation | $3.74M | $4.91M | $7.27M | $10.52M | — | -23.8% |
| Change in working capital | -$775.30K | -$1.89M | -$16.55M | $21.94M | — | +59.0% |
| Operating cash flow | -$15.66M | -$29.70M | -$28.45M | -$48.61M | — | +47.3% |
| Capital expenditure | -$17.05K | -$33.58K | -$85.01K | -$690.94K | — | +49.2% |
| Investing cash flow | $476.80K | $1.11M | -$77.36K | -$686.05K | — | -57.0% |
| Share buybacks | — | $0 | $0 | -$3.98M | -$2.36M | — |
| Financing cash flow | $4.45M | $3.77M | -$5.37M | $17.82M | — | +17.9% |
| Free cash flow | -$15.67M | -$29.73M | -$28.54M | -$49.30M | — | +47.3% |
| End cash position | $74.52M | $85.19M | $109.93M | $143.76M | — | -12.5% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
| Line item | 2026-06-30 | 2025-12-31 | 2025-06-30 | YoY |
|---|---|---|---|---|
| Cash & equivalents | $127.91M | $74.52M | $62.83M | +71.6% |
| Cash & short-term investments | $127.91M | $74.52M | $62.83M | +71.6% |
| Accounts receivable | $150.00K | — | — | — |
| Total current assets | $132.41M | $77.38M | $65.36M | +71.1% |
| Property, plant & equipment | $1.11M | $862.91K | $1.12M | +28.3% |
| Total assets | $133.58M | $78.26M | $66.52M | +70.7% |
| Total current liabilities | $26.36M | $25.17M | $28.52M | +4.7% |
| Current debt | $4.70M | $4.98M | $6.64M | -5.6% |
| Long-term debt | $1.03M | $1.14M | — | -9.7% |
| Total debt | $6.09M | $6.26M | $6.85M | -2.7% |
| Total liabilities | $44.12M | $42.91M | $28.60M | +2.8% |
| Retained earnings | -$345.16M | -$328.79M | -$324.65M | -5.0% |
| Shareholder equity | $89.45M | $35.35M | $37.91M | +153.1% |
| Working capital | $106.05M | $52.20M | $36.85M | +103.1% |
| Net tangible assets | $89.45M | $35.35M | $37.91M | +153.1% |
| Shares issued | 82.59M | 59.23M | 58.91M | +39.4% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.19 | — | — |
| Mar 2026 | -0.08 | — | — |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.23 | 1 | $0 | — |
| Next quarter | -0.24 | 1 | $0 | — |
| Current year | -0.51 | 5 | $1.96M | -74.5% |
| Next year | -0.59 | 5 | $4.50M | +129.6% |
Analyst targets & ownership
Mean target$9.91
High target$17.45
Low target$7.00
Implied upside241.67%
Analyst count6
ConsensusSTRONG BUY
Strong buy / Buy0 / 6
Hold0
Sell / Strong sell0 / 0
Held by insiders11.39%
Held by institutions36.04%
Institutions holding43
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
2.99
-3.11% from price
SMA 20
3.11
-6.66% from price
SMA 50
3.53
-17.78% from price
SMA 100
3.63
-20.12% from price
SMA 200
3.36
-13.76% from price
EMA 12
3.02
-3.87% from price
EMA 26
3.19
-9.23% from price
EMA 50
3.38
-14.23% from price
RSI (14)
39.1
Neutral
MACD (12,26,9)
-0.18
Hist -0.01
ATR (14)
0.27
9.47% of price
Realised vol 30D
69.6%
Annualised
Bollinger upper
3.47
20, 2σ
Bollinger lower
2.74
20, 2σ
50 / 200 cross
Golden
3.53 vs 3.36
Trend bias
Below 200
-13.76%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.87
Less volatile than market
Correlation to SPY
0.12
Largely independent
Realised vol 30D
69.6%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-41.4%
Peak to trough
Max drawdown 5Y
-93.4%
Peak to trough
ATR 14
0.27
9.47% of price
Beta (reported)
0.54
5Y monthly, from filing
Short interest
Shares short
2.10M
Prior 2.11M
Change vs prior
-0.4%
Shorts covering
% of float
3.68%
Normal
% of shares out
3.13%
Against total outstanding
Days to cover
8.9
Crowded exit
Float
42.09M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 14, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Sep 10, 26 | Chardan Capital | INITIATED | — | Buy |
| Apr 6, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Nov 24, 25 | Guggenheim | INITIATED | — | Buy |
| Sep 18, 25 | LUCID CAPITAL MARKETS | INITIATED | — | Buy |
| Aug 15, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 6, 25 | Leerink Partners | INITIATED | — | Outperform |
| Apr 3, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jan 27, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Sep 18, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jul 22, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jun 28, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
6-K · 2026-09-25
Corporate Changes & Voting Matters
6-K · 2026-09-22
Corporate Changes & Voting Matters
6-K · 2026-09-10
Corporate Changes & Voting Matters
6-K · 2026-09-09
Corporate Changes & Voting Matters
6-K · 2026-08-12
Corporate Changes & Voting Matters
6-K · 2026-07-06
Corporate Changes & Voting Matters
6-K · 2026-04-17
Corporate Changes & Voting Matters
6-K · 2026-04-02
Headlines
Adagene Announces NMPA Clearance of Investigational New Drug Application for ADG138, a Novel HER2xCD3 Double-Masked Bispecific T-Cell Engager
GlobeNewswire · 15d ago
Adagene Announces that Third Arc Bio Has Selected First Lead Candidate under Amended Strategic Collaboration for Development of Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology
GlobeNewswire · 27d ago
Chardan Initiates Adagene at Buy With $9 Price Target
MT Newswires · 27d ago
Adagene Receives Milestone Payment From Exelixis
MT Newswires · 28d ago
Adagene Achieves Milestone in Collaboration with Exelixis for Advancement of SAFEbody® Antibody-Drug Conjugate Candidates
GlobeNewswire · 28d ago
Adagene to Participate in Three Upcoming Investor Conferences
GlobeNewswire · 48d ago
Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates
GlobeNewswire · 56d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.